The Resistance Mechanisms of Proteasome Inhibitor Bortezomib

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2013 Nov 21

PMID 24252210

Citations 68

Authors

Shuqing Lu

Jianmin Wang

Affiliations

Soon will be listed here.

Abstract

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy against multiple myeloma and several non-Hodgkin's lymphoma subtypes, and has a potential therapeutic role against other malignancy diseases. However, intrinsic and acquired resistance to bortezomib may limit its efficacy. In this article, we discuss recent advances in the molecular understanding of bortezomib resistance. Resistance mechanisms discussed include mutations of PSMB5 and the up-regulation of proteasome subunits, alterations of gene and protein expression in stress response, cell survival and antiapoptotic pathways, and multidrug resistance.

Citing Articles

Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.

St Thomas N, Christopher B, Reyes L, Robinson R, Golick L, Zhu X Biomolecules. 2025; 15(1).

PMID: 39858470 PMC: 11763779. DOI: 10.3390/biom15010076.

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.

Plakoula E, Kalampounias G, Alexis S, Verigou E, Kourakli A, Zafeiropoulou K Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852147 PMC: 11763810. DOI: 10.3390/cimb47010032.

Comparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools.

Seker S, Sahin B, Yerlikaya A J Cell Mol Med. 2025; 29(1):e70254.

PMID: 39799471 PMC: 11725179. DOI: 10.1111/jcmm.70254.

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.

Li J, Parthasarathy A, Kannappan A, Arsang-Jang S, Dong J, Cheng C Oncologist. 2024; 29(11):e1552-e1564.

PMID: 39250742 PMC: 11639189. DOI: 10.1093/oncolo/oyae244.

Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.

Tyrna P, Procyk G, Szeleszczuk L, Mlynarczuk-Bialy I Int J Mol Sci. 2024; 25(16).

PMID: 39201634 PMC: 11354503. DOI: 10.3390/ijms25168949.

References

Groll M, Berkers C, Ploegh H, Ovaa H . Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14(3):451-6. DOI: 10.1016/j.str.2005.11.019. View

Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S . Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10(10):3371-6. DOI: 10.1158/1078-0432.CCR-03-0508. View

Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R . Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma. 2003; 44(3):543-5. DOI: 10.1080/1042819021000037895. View

McConkey D, Zhu K . Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11(4-5):164-79. DOI: 10.1016/j.drup.2008.08.002. View

Murata S, Yashiroda H, Tanaka K . Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009; 10(2):104-15. DOI: 10.1038/nrm2630. View

Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A . Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010; 24(8):1506-12. DOI: 10.1038/leu.2010.137. View

Jung H, Chen Z, Fayad L, Wang M, Romaguera J, Kwak L . Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol. 2011; 40(2):107-18.e2. PMC: 3398482. DOI: 10.1016/j.exphem.2011.10.004. View

Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F . Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004; 23(4):667-75. DOI: 10.1200/JCO.2005.03.108. View

Bataille R, Robillard N, Avet-Loiseau H, Harousseau J, Moreau P . CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica. 2005; 90(5):706-7. View

10.

Rajkumar S, Richardson P, Hideshima T, Anderson K . Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005; 23(3):630-9. DOI: 10.1200/JCO.2005.11.030. View

11.

Oerlemans R, Franke N, Assaraf Y, Cloos J, van Zantwijk I, Berkers C . Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112(6):2489-99. DOI: 10.1182/blood-2007-08-104950. View

12.

Verbrugge S, Assaraf Y, Dijkmans B, Scheffer G, Al M, den Uyl D . Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients.... J Pharmacol Exp Ther. 2012; 341(1):174-82. DOI: 10.1124/jpet.111.187542. View

13.

Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N . The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002; 10(5):609-18. DOI: 10.1016/s0969-2126(02)00748-7. View

14.

Lu S, Chen Z, Yang J, Chen L, Zhou H, Xu X . The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Int J Lab Hematol. 2009; 32(1 Pt 1):e123-31. DOI: 10.1111/j.1751-553X.2009.01145.x. View

15.

Que W, Chen J, Chuang M, Jiang D . Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS. 2012; 120(3):195-203. DOI: 10.1111/j.1600-0463.2011.02836.x. View

16.

Chng W, Gualberto A, Fonseca R . IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia. 2005; 20(1):174-6. DOI: 10.1038/sj.leu.2403997. View

17.

Chen P, Hochstrasser M . Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell. 1996; 86(6):961-72. DOI: 10.1016/s0092-8674(00)80171-3. View

18.

Wang L, Kumar S, Fridley B, Kalari K, Moon I, Pelleymounter L . Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res. 2008; 14(11):3503-13. PMC: 2778274. DOI: 10.1158/1078-0432.CCR-07-5150. View

19.

Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609-17. DOI: 10.1056/NEJMoa030288. View

20.

Kisselev A, Akopian T, Castillo V, GOLDBERG A . Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell. 1999; 4(3):395-402. DOI: 10.1016/s1097-2765(00)80341-x. View